Advertisement
Advertisement
U.S. markets closed
S&P Futures
4,306.75 -1.00 (-0.02%) Dow Futures
34,122.00 +4.00 (+0.01%) Nasdaq Futures
13,643.75 -14.50 (-0.11%) Russell 2000 Futures
2,024.20 +0.90 (+0.04%) Crude Oil
87.11 +0.58 (+0.67%) Gold
1,790.90 +1.20 (+0.07%)
Moderna, Inc. (MRNA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 176.78 |
| Open | 176.00 |
| Bid | 167.91 x 1000 |
| Ask | 168.00 x 800 |
| Day's Range | 166.60 - 180.13 |
| 52 Week Range | 115.61 - 464.85 |
| Volume | |
| Avg. Volume | 5,186,432 |
| Market Cap | 65.706B |
| Beta (5Y Monthly) | 1.60 |
| PE Ratio (TTM) | 4.95 |
| EPS (TTM) | 33.91 |
| Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 221.40 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
6% Est. Return
Subscribe to Yahoo Finance Plus to view Fair Value for MRNA
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Moderna, Inc.Analyst Report: Moderna, Inc.Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.RatingFair ValueEconomic Moat8 days agoMorningstar
- Zacks
Novavax (NVAX) Seeks FDA Authorization for COVID-19 Booster Dose
Novavax (NVAX) seeks label expansion from the FDA for its COVID-19 vaccine as a booster dose in adults. The vaccine is authorized as a primary two-dose regimen in adults.
- Motley Fool
Why Moderna Stock Is Sliding Today
What happened Shares of Moderna (NASDAQ: MRNA) had slid 4.2% lower at 11:26 a.m. ET on Tuesday after being down as much as 5.8% earlier in the day. The company didn't announce any negative news. However, there were a couple of factors that could be behind the decline.
- Barrons.com
Merck Jumps Into a $3.7 Billion mRNA Collaboration
Merck has been a laggard in the Covid-era race for messenger RNA technology, but it just announced a deal with privately held Orna Therapeutics.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
